HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Ambinder, R. F. Search for Related Content PubMed PubMed Citation Articles by Ambinder, R. F. Social Bookmarking                   What's this?

Epstein-Barr Virus and Hodgkin Lymphoma

Correspondence: Richard Ambinder, MD, PhD, Johns Hopkins University, Bunting-Blaustein Cancer Research Bldg., 1650 Orleans Street, Room 389, Baltimore MD 21231; phone (410) 955-5617; fax (410) 955-0960; ambinri{at}jhmi.edu

Abstract

Epstein-Barr virus (EBV) is detected in some Hodgkin lymphoma (HL) tumor cells. Primary infection is associated with infectious mononucleosis and EBV⁺ HL. Vaccines and antiviral drugs show promise in modulating the clinical course of infectious mononucleosis. Their impact on HL is entirely unknown. T-cell function may be important in the pathogenesis of HL. In HIV patients, higher CD4 counts are associated with an increased incidence of EBV⁺ HL. One of the roles of the virus in the pathogenesis of HL may be to mimic signals associated with surface immunoglobulin molecules. New approaches to imaging EBV-associated tumors may be on the horizon. Adoptive immunotherapy and virus-specific pharmacologic therapies offer promise for future treatment.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?